Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Uveal Melanoma 1Select Advanced Solid Tumors 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × tebentafusp × Clear all
NCT02570308 2023-03-21

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Immunocore Ltd

Phase 1/2 Completed
146 enrolled 26 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡